Ascletis Announces ASC47 in Combination with Semaglutide Demonstrated Up to 56.2% Greater Relative Reduction in Body Weight in Participants with Obesity Compared to Semaglutide Monotherapy

Core Insights - The gastrointestinal tolerability of ASC47 in combination with semaglutide is significantly better than that of semaglutide monotherapy, indicating a potential advantage for ASC47 in clinical applications [1] Group 1 - The incidence of vomiting in the ASC47 plus semaglutide group was 6.7%, compared to 57.1% in the semaglutide monotherapy group, highlighting a substantial difference in tolerability [1]